Ceftolozane/Tazobactam Activity Tested Against Aerobic Gram-negative Organisms Isolated From Intra-abdominal Infections in United States Hospitals (2013)

D. J. Farrell, H. S. Sader, R. K. Flamm, R. N. Jones

JMI Laboratories, North Liberty, IA, USA

INTRODUCTION

In the United States, the incidence of intra-abdominal infections (IAIs) is rising, and newer agents are needed for the treatment of these infections. Ceftolozane/tazobactam (TOL/TAZ) is a beta-lactam-beta-lactamase inhibitor combination that was approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal infections (cIAIs) in 2014. This study evaluated the activity of ceftolozane/tazobactam against aerobic gram-negative organisms isolated from cIAIs in the United States during 2013.

MATERIALS AND METHODS

In the United States, the incidence of intra-abdominal infections (IAIs) is rising, and newer agents are needed for the treatment of these infections. Ceftolozane/tazobactam (TOL/TAZ) is a beta-lactam-beta-lactamase inhibitor combination that was approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal infections (cIAIs) in 2014. This study evaluated the activity of ceftolozane/tazobactam against aerobic gram-negative organisms isolated from cIAIs in the United States during 2013.

RESULTS

This study was funded by Cubist Pharmaceuticals. Presented at IDWeek: A joint meeting of IDSA • SHEA • HIVMA • PIDS October 8-12, 2014, Philadelphia, PA

ACKNOWLEDGMENTS

REFERENCES

Ceftolozane/Tazobactam Activity Tested Against Aerobic Gram-negative Organisms Isolated From Intra-abdominal Infections in United States Hospitals (2013)

D. J. Farrell, H. S. Sader, R. K. Flamm, R. N. Jones

JMI Laboratories, North Liberty, IA, USA

INTRODUCTION

In the United States, the incidence of intra-abdominal infections (IAIs) is rising, and newer agents are needed for the treatment of these infections. Ceftolozane/tazobactam (TOL/TAZ) is a beta-lactam-beta-lactamase inhibitor combination that was approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal infections (cIAIs) in 2014. This study evaluated the activity of ceftolozane/tazobactam against aerobic gram-negative organisms isolated from cIAIs in the United States during 2013.

MATERIALS AND METHODS

In the United States, the incidence of intra-abdominal infections (IAIs) is rising, and newer agents are needed for the treatment of these infections. Ceftolozane/tazobactam (TOL/TAZ) is a beta-lactam-beta-lactamase inhibitor combination that was approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal infections (cIAIs) in 2014. This study evaluated the activity of ceftolozane/tazobactam against aerobic gram-negative organisms isolated from cIAIs in the United States during 2013.

RESULTS

This study was funded by Cubist Pharmaceuticals. Presented at IDWeek: A joint meeting of IDSA • SHEA • HIVMA • PIDS October 8-12, 2014, Philadelphia, PA

ACKNOWLEDGMENTS

REFERENCES

Ceftolozane/Tazobactam Activity Tested Against Aerobic Gram-negative Organisms Isolated From Intra-abdominal Infections in United States Hospitals (2013)

D. J. Farrell, H. S. Sader, R. K. Flamm, R. N. Jones

JMI Laboratories, North Liberty, IA, USA

INTRODUCTION

In the United States, the incidence of intra-abdominal infections (IAIs) is rising, and newer agents are needed for the treatment of these infections. Ceftolozane/tazobactam (TOL/TAZ) is a beta-lactam-beta-lactamase inhibitor combination that was approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal infections (cIAIs) in 2014. This study evaluated the activity of ceftolozane/tazobactam against aerobic gram-negative organisms isolated from cIAIs in the United States during 2013.

MATERIALS AND METHODS

In the United States, the incidence of intra-abdominal infections (IAIs) is rising, and newer agents are needed for the treatment of these infections. Ceftolozane/tazobactam (TOL/TAZ) is a beta-lactam-beta-lactamase inhibitor combination that was approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal infections (cIAIs) in 2014. This study evaluated the activity of ceftolozane/tazobactam against aerobic gram-negative organisms isolated from cIAIs in the United States during 2013.

RESULTS

This study was funded by Cubist Pharmaceuticals. Presented at IDWeek: A joint meeting of IDSA • SHEA • HIVMA • PIDS October 8-12, 2014, Philadelphia, PA

ACKNOWLEDGMENTS

REFERENCES

Ceftolozane/Tazobactam Activity Tested Against Aerobic Gram-negative Organisms Isolated From Intra-abdominal Infections in United States Hospitals (2013)

D. J. Farrell, H. S. Sader, R. K. Flamm, R. N. Jones

JMI Laboratories, North Liberty, IA, USA

INTRODUCTION

In the United States, the incidence of intra-abdominal infections (IAIs) is rising, and newer agents are needed for the treatment of these infections. Ceftolozane/tazobactam (TOL/TAZ) is a beta-lactam-beta-lactamase inhibitor combination that was approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal infections (cIAIs) in 2014. This study evaluated the activity of ceftolozane/tazobactam against aerobic gram-negative organisms isolated from cIAIs in the United States during 2013.

MATERIALS AND METHODS

In the United States, the incidence of intra-abdominal infections (IAIs) is rising, and newer agents are needed for the treatment of these infections. Ceftolozane/tazobactam (TOL/TAZ) is a beta-lactam-beta-lactamase inhibitor combination that was approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal infections (cIAIs) in 2014. This study evaluated the activity of ceftolozane/tazobactam against aerobic gram-negative organisms isolated from cIAIs in the United States during 2013.

RESULTS

This study was funded by Cubist Pharmaceuticals. Presented at IDWeek: A joint meeting of IDSA • SHEA • HIVMA • PIDS October 8-12, 2014, Philadelphia, PA

ACKNOWLEDGMENTS

REFERENCES

Ceftolozane/Tazobactam Activity Tested Against Aerobic Gram-negative Organisms Isolated From Intra-abdominal Infections in United States Hospitals (2013)

D. J. Farrell, H. S. Sader, R. K. Flamm, R. N. Jones

JMI Laboratories, North Liberty, IA, USA

INTRODUCTION

In the United States, the incidence of intra-abdominal infections (IAIs) is rising, and newer agents are needed for the treatment of these infections. Ceftolozane/tazobactam (TOL/TAZ) is a beta-lactam-beta-lactamase inhibitor combination that was approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal infections (cIAIs) in 2014. This study evaluated the activity of ceftolozane/tazobactam against aerobic gram-negative organisms isolated from cIAIs in the United States during 2013.

MATERIALS AND METHODS

In the United States, the incidence of intra-abdominal infections (IAIs) is rising, and newer agents are needed for the treatment of these infections. Ceftolozane/tazobactam (TOL/TAZ) is a beta-lactam-beta-lactamase inhibitor combination that was approved by the US Food and Drug Administration for the treatment of complicated intra-abdominal infections (cIAIs) in 2014. This study evaluated the activity of ceftolozane/tazobactam against aerobic gram-negative organisms isolated from cIAIs in the United States during 2013.

RESULTS

This study was funded by Cubist Pharmaceuticals. Presented at IDWeek: A joint meeting of IDSA • SHEA • HIVMA • PIDS October 8-12, 2014, Philadelphia, PA

ACKNOWLEDGMENTS

REFERENCES